| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
The implementation of targeted therapies for acute myeloid leukemia has been challenged by complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here, we report initial findings from the Beat AML program on a cohort of 672 tumor specimens collected from 562 patients. We assessed these specimens using whole exome sequencing, RNA-sequencing, and ex vivo drug sensitivity analyses. Our data reveal novel mutational events not previously detected in AML. We show association of drug response with mutational status, including instances of drug sensitivity that are specific to combinatorial mutational events. Integration with RNA-sequencing also revealed gene expression signatures, which predict a role of specific gene networks in drug response. Collectively, this report offers a dataset, accessible by the Beat AML data viewer (www.vizome.org), that can be leveraged to address clinical, genomic, transcriptomic, and functional inquiries into the biology of AML.
- Study Weblinks:
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Longitudinal
- Total number of consented subjects: 583
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
All patients with a presumed diagnosis of AML were eligible for specimen collection on this study (listed at clinicaltrails.gov - NCT 01728402).
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Exome Sequencing Illumina Nextera Rapid Capture Exome N/A N/A Whole Exome Sequencing Illumina HiSeq 2500 N/A N/A Custom Capture Sequencing Illumina HiSeq 2500 N/A N/A RNA Sequencing Agilent SureSelect 38Mb N/A N/A - Study History
Samples were obtained according to the Declaration of Helsinki. All patients gave consent to participate in this study, which had the approval and guidance of the institutional review boards at Oregon Health & Science University (OHSU), University of Utah, University of Texas Medical Center (UT Southwestern), Stanford University, University of Miami, University of Colorado, University of Florida, National Institutes of Health (NIH), Fox Chase Cancer Center and University of Kansas (KUMC). Samples were sent to the coordinating center (OHSU; IRB#9570) where they were coded and processed.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Leukemia, Myeloid, Acute
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Jeffrey W. Tyner, PhD. Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA.
-
Funding Source
- The Leukemia and Lymphoma Society, Beat AML. Rye Brook, NY, USA.
- NIH/NCI, 1U54CA224019. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- NIH/NCI, 1U01CA217862. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- NIH/NCI, 3P30CA069533-18S5. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator